(Q30405727)

English

Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study (English)

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

Bradley J. Monk

4

object named as

Bradley J Monk

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

author name string

Robert A Burger

1

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Mark F Brady

2

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Michael A Bookman

3

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Joan L Walker

5

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Howard D Homesley

6

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Jeffrey Fowler

7

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Benjamin E Greer

8

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Matthew Boente

9

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Gini F Fleming

10

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Peter C Lim

11

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Stephen C Rubin

12

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Noriyuki Katsumata

13

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Sharon X Liang

14

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

language of work or name

0 references

publication date

17 March 2014

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

32

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

12

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

1210-1217

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Bowel perforation in non-small cell lung cancer after bevacizumab therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Mechanical obstruction of the small bowel and colon.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

A case of bowel perforation after neoadjuvant chemotherapy for advanced epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Gastrointestinal perforation due to bevacizumab in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

The incidence of anastomotic leaks in patients undergoing colorectal surgery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Systematic review of the definition and measurement of anastomotic leak after gastrointestinal surgery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

The prognostic significance of angiogenesis in epithelial ovarian carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Vascular endothelial growth factor expression in early stage ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Tumor angiogenesis in advanced stage ovarian carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Free perforation in Crohn's disease: I. A survey of 99 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Spontaneous free perforation and perforated abscess in 30 patients with Crohn's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Free perforation in Crohn's disease: a report of 33 cases and review of literature.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

20 June 2018

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

26 November 2018

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

26 November 2018

Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

26 November 2018

Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

26 November 2018

Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

26 November 2018

Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

26 November 2018

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

26 November 2018

The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

26 November 2018

The Angiogenesis Inhibitor, Endostatin, Does Not Affect Murine Cutaneous Wound Healing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986384

26 November 2018

Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ultimate fate of the leaking intestinal anastomosis: does leak mean permanent stoma?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of perioperative treatment with TNP-470 on the resistance of colonic anastomoses in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adverse effects of the antiangiogenic agent angiostatin on the healing of experimental colonic anastomoses

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intestinal perforation secondary to paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiogenesis inhibitor TNP-470 prevents implanted liver metastases after partial hepatectomy in an experimental model without impairing wound healing

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24637999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2013.53.6524

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30405727&oldid=2032768633"